Mito Genome Sequencing & Deletion Testing
New York
Approved
Conditions
- Chronic Intestinal Pseudoobstruction with Myopathy and Ophthalmoplegia (CIPO)
- Chronic Progressive External Ophthalmoplegia (CPEO)
- Oxidative Phosphorylation (OXPHOS) Deficiency
- Complex I Deficiency
- Complex III Deficiency
- Complex IV(Cytochrome C Oxidase) Deficiency
- Complex V (ATP Synthesis) Deficiency
- Diabetes and Hearing Loss
- Kearns-Sayre Syndrome (KSS)
- Lactic acidosis
- Lebers Hereditary Optic Neuropathy (LHON)
- Maternally Inherited Deafness or Aminoglycoside-Induced Deafness
- Maternally Inherited Diabetes and Deafness (MIDD)
- Maternally Inherited Diabetes Mellitus (MIDM)
- Mitochondrial Encephalomyopathy with Lactic Acidosis and Stroke-Like Episodes (MELAS)
- Mitochondrial Myopathy (MM)
- Mitochondrial Neurogastrointestinal Encephalopathy Syndrome (MNGIE)
- Myoclonic Epilepsy with Ragged-Red Fibers (MERRF)
- Neurogenic Weakness with Ataxia and Retinitis Pigmentosa (NARP)
- Optic Atrophy
- Pearson Syndrome
- Primary Coenzyme Q10 Deficiency
- Sensorineural Hearing Loss (SNHL)
Clinical Utility
- Molecular confirmation of a clinical diagnosis
- Testing of patients suspected of having a mitochondrial disorder
Lab Method
- Next-Gen Sequencing
Test Code
554
CPT Codes*
81460x1, 81465x1
ABN Required
No
Turnaround Time**
4 weeks
Preferred Specimen
Alternative Specimen
*The CPT codes provided are based on AMA guidelines and are for informational purposes only. CPT coding is the sole responsibility of the billing party. Please direct any questions regarding coding to the payer being billed.
**Turnaround times are estimates and begin once the sample(s) begin processing at the GeneDx lab and could be extended in situations outside GeneDx’s control.
Billing
Targeted Variant Testing